Résultats de la recherche ARCADIA : La dysplasie fibromusculaire est une maladie diffuse qui peut justifier un bilan d’imagerie sur plusieurs territoires artériels.

La dysplasie fibromusculaire (DFM) est une maladie longtemps considérée comme rare, en fait rarement diagnostiquée parce que souvent méconnue. C’est une maladie artérielle non-athéroscléreuse et non-inflammatoire qui touche particulièrement les artères des reins et les artères à destinée cérébrale. La DFM est quatre fois plus fréquente chez la femme que chez l’homme. Elle est identifiée par la présence de rétrécissements des artères (sténoses) caractéristiques à l’imagerie des artères. Elle peut se compliquer de dissections (clivage d’une des parois de l’artère) ou d’anévrysmes (poche, ou dilatation localisée de l’artère qui communique avec l’artère). Toutefois les dissections et les anévrysmes peuvent se voir dans d’autres maladies artérielles que la DFM.

La dysplasie fibromusculaire est généralement reconnue parce que les patients ont des symptômes. Les symptômes sont différents en fonction de l’artère touchée par la maladie. En cas d’atteinte rénale il s’agit souvent d’une hypertension artérielle, qui est le symptôme habituel de sténose des artères des reins ; de signes neurologiques (migraine, bourdonnements d’oreille ou symptômes des complications neurologiques des sténoses comme l’accident vasculaire cérébral en cas d’atteinte des artères du cou ou du cerveau). L’existence de symptômes sur un seul territoire artériel – rénal ou cérébral – n’exclut pas la présence de lésions artérielles sur un autre territoire.

La recherche effectuée sur le registre ARCADIA a permis de préciser la situation. Elle a inclus des patients porteurs de dysplasie fibromusculaire sur 12 villes en France et en Belgique. L’objectif était de rechercher avec quelle fréquence la maladie atteint non pas un seul territoire artériel, mais plusieurs. Dans ce but, les participants donnaient leur consentement pour avoir deux imageries (par angioscanner ou par angio-IRM), l’une pour visualiser les artères viscérales (abdomen et reins), l’autre pour visualiser les artères à destinée cérébrale.

Les résultats dévoilés en Juin 2017, montre que dans près de la moitié des cas la maladie touche deux territoires. Plus précisément, parmi 469 patients, 225 ( 48.0%) avaient des sténoses sur plus d’un territoire. De plus, 86 des 244 patients ayant des sténoses sur un seul territoire avaient aussi des dissections et/ou des anévrysmes sur un autre territoire. Au total, 311 patients (66.3%) avaient des sténoses (spécifiques de la DFM), et des dissections ou anévrysmes (non spécifiques de la DFM) sur plus d’un territoire. Les sténoses des artères rénales et des artères à destinée cérébrale étaient bilatérales dans 49% and 75% des cas, respectivement.

Ces données suggèrent que la DFM est une maladie diffuse. Elles ont des implications pratiques.

D’une part, les patients porteurs de DFM doivent être informés qu’ils peuvent avoir des lésions sur des territoires artériels asymptomatiques. De l’autre, leur médecin doit connaître les situations où il est utile d’examiner ces territoires : (1) En cas de présentation neurologique, la fréquence des sténoses des artères rénales est 3,4 fois plus élevée chez les personnes porteuses de DFM qui ont une hypertension que chez celles qui ont une tension normale ; il est alors logique de proposer une imagerie des artères rénales car une dilatation des artères rétrécies peut être envisagée pour traiter l’hypertension ; (2) En cas de présentation rénale, la présence de sténoses des artères à destinée cérébrale est 1,9 fois plus élevée si l’atteinte rénale est bilatérale plutôt qu’unilatérale ; on peut donc envisager une imagerie des artères cervico-encéphalique chez de tels patients.

Auteurs de la recherche : Plouin PF, Baguet JP, Thony F, Ormezzano O, Azarine A, Silhol F, Oppenheim C, Bouhanick B, Boyer L, Persu A, Hammer F, Gosse P, Mounier-Vehier C, Le Hello C, Jeunemaitre X, Azizi M, Amar L, Chatellier G, Mousseaux G, Touzé E, and the Assessment of Renal and Cervical Artery DysplasIA (ARCADIA) Investigators. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: the ARCADIA registry. Hypertension 2017 (in press)

Date de mise en ligne : 6 juillet 2017

L’unité d’hypertension artérielle de l’hôpital européen Georges Pompidou (Paris) est impliquée dans de nombreuses publications scientifiques. Voici une liste non exhaustive des articles scientifiques parus dans la presse médicale à comité de lecture

2020

2019

1. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, et al. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019.Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040451.
2. Azizi M, Rossignol P, Hulot JS. Emerging Drug Classes and Their Potential Use in Hypertension. 2019; 74(5): 1075-83.
3. Courand PY, Dinic M, Lorthioir A, Bobrie G, Grataloup C, Denarie N, Azizi M, Amar L Resistant Hypertension and Atherosclerotic Renal Artery Stenosis: Effects of Angioplasty on Ambulatory Blood Pressure. A Retrospective Uncontrolled Single-Center Study. Hypertension. 2019;74(6): 1516-23.
4. Azizi M, Courand PY, Denolle T, Delsart P, Zhygalina V, Amar L, et al.A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension. J Hypertens. 2019; 37(8): 1722-8.
5. Amar L, Azizi M. [Secondary hypertension in women]. Presse Med. 2019;48(11 Pt 1): 1265-8.
6. Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, et al. Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. J Am Coll Cardiol. 2019;73(1): 58-66.
7. Assie G, Jouinot A, Fassnacht M, Libe R, Garinet S, Jacob L, et al. Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.JAMA Oncol. 2019.
8. Ben Aim L, Pigny P, Castro-Vega LJ, Buffet A, Amar L, Bertherat J, et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet. 2019;56(8): 513-20.
9. Boulestreau R, Cremer A, Lorthioir A, Rubin S, Tharaux PL, Persu A, et al. [Malignant hypertension: A bright future]. Presse Med. 2019.
10. Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, Libe R, et al.Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. J Clin Endocrinol Metab. 2019; 104(4): 1109-18.
11. Calsina B, Castro-Vega LJ, Torres-Perez R, Inglada-Perez L, Curras-Freixes M, Roldan-Romero JM, et al.Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics. 2019; 9(17): 4946-58.
12. Carcel C, Neal B, Oparil S, Rogers K, Narkiewicz K, Wang JG, et al. Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study. J Hypertens. 2019;37(11): 2216-24.
13. Cornu E, Belmihoub I, Burnichon N, Grataloup C, Zinzindohoue F, Baron S, et al. [Phaeochromocytoma and paraganglioma]. Rev Med Interne. 2019;40(11): 733-41.
14. De Sousa K, Abdellatif AB, El Zein RM, Zennaro MC. Molecular mechanisms in primary aldosteronism. J Mol Endocrinol. 2019;242(3): R67-R79.
15. Faucon AL, Bobrie G, Clement O. Nephrotoxicity of iodinated contrast media: From pathophysiology to prevention strategies. Eur J Radiol. 2019;116: 231-41.
16. Faucon AL, Bourillon C, Grataloup C, Baron S, Bernadet-Monrozies P, Vidal-Petiot E, et al. Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. Am J Kidney Dis. 2019;73(4): 566-71.
17. Goncalves J, Lussey-Lepoutre C, Favier J, Gimenez-Roqueplo AP, Castro-Vega LJ.Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Ann Endocrinol (Paris). 2019; 80(3): 159-62.
18. Goppner C, Orozco IJ, Hoegg-Beiler MB, Soria AH, Hubner CA, Fernandes-Rosa FL, et al.Pathogenesis of hypertension in a mouse model for human CLCN2 related hyperaldosteronism. Nat Commun. 2019; 10(1): 4678.
19. Hamdidouche I, Gosse P, Cremer A, Lorthioir A, Delsart P, Courand PY, et al. Clinic versus Ambulatory Blood Pressure in Patients with Resistant Hypertension: Impact of Antihypertensive Medication Non-adherence: A post-hoc analysis the DENERHTN (Renal Denervation for Resistant Hypertension) study. Hypertension. 2019;74: 1096–103.
20. Job S, Georges A, Burnichon N, Buffet A, Amar L, Bertherat J, et al. Transcriptome analysis of lncRNAs in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2019.
21. Lorthioir A, Belmihoub I, Fouassier D, Azizi M, Amar L. [Spironolactone in resistant essential hypertension]. Presse Med. 2019;48(12): 1431-8.
22. Lussey-Lepoutre C, Bellucci A, Burnichon N, Amar L, Buffet A, Drossart T, et al.Succinate detection using in vivo (1)H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. Eur J Nucl Med Mol Imaging. 2019.
23. Marques P, Courand PY, Gouin-Thibault I, Zhygalina V, Bergerot D, Salem JE, et al.P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. J Hypertens. 2019; 37(11): 2225-31.
24. Pieragostini R, Perrin G, Nevoret C, Amar L, Jannot AS, Sabatier P, et al. Conditional prescriptions of oral antihypertensive drugs for the management of hypertension urgencies in the inpatient setting: An observational study. J Clin Pharm Ther. 2019: Sep 28. doi: 10.1111/jcpt.13059.
25. Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, et al. Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension. 2019;74(4): 800-8.
26. Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, et al. Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization.J Clin Endocrinol Metab. 2019.
27. Touze E, Southerland AM, Boulanger M, Labeyrie PE, Azizi M, Bouatia-Naji N, et al.Fibromuscular Dysplasia and Its Neurologic Manifestations: A Systematic Review. JAMA Neurol. 2019; 76(2): 217-26.
28. Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lepine C, Venisse A, Robidel E, Verkarre V, Meatchi T, Sibony M, Amar L, Bertherat J, de Reynies A, Londono-Vallejo A, Favier J, Castro-Vega LJ, Gimenez-Roqueplo AP. Telomerase activation and atrx mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2019;25:760-770
29. Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, de la Fouchardiere C, Valdes N, Riccardi N, Do Cao C, Bertherat J, Goichot B, Beuschlein F, Drui D, Canu L, Niccoli P, Laboureau S, Tabarin A, Leboulleux S, Calsina B, Libe R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers H, Fassnacht M, Robledo M, Borget I, Baudin E, European Network for the Study of Adrenal T. Prognosis of malignant pheochromocytoma and paraganglioma (mapp-prono study): An ens@t retrospective study. J Clin Endocrinol Metab. 2019
30. Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, De Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, Kadian-Dodov D, Kim ESH, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touze E, Van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF, Working Group H, the Kidney’ of the European Society of H, the Society for Vascular M. First international consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2019;37:229-252
31. Gornik Co-Chair HL, Persu Co-Chair A, Adlam D, Aparicio LS, Azizi M, Boulanger M, Bruno RM, de Leeuw P, Fendrikova-Mahlay N, Froehlich J, Ganesh SK, Gray BH, Jamison C, Januszewicz A, Jeunemaitre X, Kadian-Dodov D, Kim ES, Kovacic JC, Mace P, Morganti A, Sharma A, Southerland AM, Touze E, van der Niepen P, Wang J, Weinberg I, Wilson S, Olin JW, Plouin PF. First international consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019:1358863X18821816
32. Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, Libe R, Ajzenberg C, Bernardeschi D, Cariou B, Chabolle F, Chabre O, Darrouzet V, Delemer B, Desailloud R, Goichot B, Esvant A, Offredo L, Herman P, Laboureau S, Lefebvre H, Pierre P, Raingeard I, Reznik Y, Sadoul JL, Hadoux J, Tabarin A, Tauveron I, Zenaty D, Favier J, Bertherat J, Baudin E, Amar L, Gimenez-Roqueplo AP, French Group of Endocrine T, network C. Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma. J Clin Endocrinol Metab. 2019
33. Bruno RM, Marais L, Khettab H, Lorthioir A, Frank M, Jeunemaitre X, Laurent S, Boutouyrie P, Azizi M. Deep vascular phenotyping in patients with renal multifocal fibromuscular dysplasia. Hypertension. 2019;73:371-378
34. Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, O’Byrne MM, Bouajila S, Georges A, Mishra K, Braund PS, d’Escamard V, Huang S, Margaritis M, Nelson CP, de Andrade M, Kadian-Dodov D, Welch CA, Mazurkiewicz S, Jeunemaitre X, Consortium D, Wong CMY, Giannoulatou E, Sweeting M, Muller D, Wood A, McGrath-Cadell L, Fatkin D, Dunwoodie SL, Harvey R, Holloway C, Empana JP, Jouven X, Group CADS, Olin JW, Gulati R, Tweet MS, Hayes SN, Samani NJ, Graham RM, Motreff P, Bouatia-Naji N. Association of the phactr1/edn1 genetic locus with spontaneous coronary artery dissection. J Am Coll Cardiol. 2019;73:58-66
35. Zennaro MC. From transcripts to proteins. Hypertension. 2019;73:284-285

2018

1. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L, Investigators R-H. Endovascular ultrasound renal denervation to treat hypertension (radiance-htn solo): A multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335-2345
2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, et al.. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension: The task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. J Hypertens. 2018;36:1953-2041
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. European Heart Journal. 2018;39:3021-3104
4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M et al. 2018 practice guidelines for the management of arterial hypertension of the european society of hypertension (ESH) and the european society of cardiology (ESC). Blood Press. 2018;27:314-340
5. Touze E, Southerland AM, Boulanger M, Labeyrie PE, Azizi M, Bouatia-Naji N, Debette S, Gornik HL, Hussain SM, Jeunemaitre X, Joux J, Kirton A, Le Hello C, Majersik JJ, Mocco J, Persu A, Sharma A, Worrall BB, Olin JW, Plouin PF. Fibromuscular dysplasia and its neurologic manifestations: A systematic review. JAMA Neurol. 2018, Oct 1. Epub
6. Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL. Vemurafenib and cobimetinib overcome resistance to vemurafenib in braf-mutant ganglioglioma. Neurology. 2018;91:523-525
7. Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P. Chemoresistant pleomorphic rhabdomyosarcoma: Whole exome sequencing reveals underlying cancer predisposition and therapeutic options. J Med Genet. 2018
8. Schmieder RE, Mahfoud F, Azizi M, Pathak A, Dimitriadis K, Kroon AA, Ott C, Scalise F, Mancia G, Tsioufis C, Members of the ESHWGoIToH. European society of hypertension position paper on renal denervation 2018. J Hypertens. 2018;36:2042-2048
9. Renaudin K, Smati S, Wargny M, Al Ghuzlan A, Aubert S, Leteurtre E, Patey M, Sibony M, Sturm N, Tissier F, Amar L, Bertherat J, Berthozat C, Chabre O, Do Cao C, Haissaguerre M, Pierre P, Briet C, Vezzosi D, Lifante JC, Pattou F, Mirallie E, Baudin E, Cariou B, Libe R, Drui D, for Comete-Cancer N. Clinicopathological description of 43 oncocytic adrenocortical tumors: Importance of ki-67 in histoprognostic evaluation. Mod Pathol. 2018;31:1708-1716
10. Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano J-P, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey J-M, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo A-P, Giraud S, Lapointe A-S, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D. Guidelines for reporting secondary findings of genome sequencing in cancer genes: The sfmpp recommendations. European Journal of Human Genetics. 2018;26:1732-1742
11. Postel-Vinay N, Reach G, Eveillard P. [adherence and new technologies: A new look at an old problem]. Med Sci (Paris). 2018;34:723-729
12. Postel-Vinay N, Bobrie G, Savard S, Persu A, Amar L, Azizi M, Parati G. Home blood pressure measurement and digital health: Communication technologies create a new context. J Hypertens. 2018;36:2125-2131
13. Meneton P, Hoertel N, Wiernik E, Lemogne C, Ribet C, Bonenfant S, Menard J, Goldberg M, Zins M. Work environment mediates a large part of social inequalities in the incidence of several common cardiovascular risk factors: Findings from the gazel cohort. Soc Sci Med. 2018;216:59-66
14. Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, Mahfoud F, Schmieder RE, Weber M, Nanto S, Azizi M. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115-129
15. Maiolino G, Ceolotto G, Battistel M, Barbiero G, Cesari M, Amar L, Caroccia B, Padrini R, Azizi M, Rossi GP. Macrolides for kcnj5-mutated aldosterone-producing adenoma (mapa): Design of a study for personalized diagnosis of primary aldosteronism. Blood Press. 2018;27:200-205
16. Macquart de Terline D, Diop BI, Bernard M, Do B, Ikama MS, N’Guetta R, Balde DM, Tchabi Y, Sidi Aly A, Ali Toure I, Zabsonre P, Damorou JF, Takombe JL, Narayanan K, Fernandez C, Tafflet M, Plouin PF, Empana JP, Marijon E, Jouven X, Antignac M. Substandard drugs among five common antihypertensive generic medications: An analysis from 10 african countries. J Hypertens. 2018;36:395-401
17. Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A, Hoogewijs D, Buffet A, Knight SJL, Gad S, Couve S, Chesnel F, Pacault M, Lindenbaum P, Job S, Dumont S, Besnard T, Cornec M, Dreau H, Pentony M, Kvikstad E, Deveaux S, Burnichon N, Ferlicot S, Vilaine M, Mazzella JM, Airaud F, Garrec C, Heidet L, Irtan S, Mantadakis E, Bouchireb K, Debatin KM, Redon R, Bezieau S, Bressac-de Paillerets B, Teh BT, Girodon F, Randi ML, Putti MC, Bours V, Van Wijk R, Gothert JR, Kattamis A, Janin N, Bento C, Taylor JC, Arlot-Bonnemains Y, Richard S, Gimenez-Roqueplo AP, Cario H, Gardie B. Identification of a new vhl exon and complex splicing alterations in familial erythrocytosis or von hippel-lindau disease. Blood. 2018;132:469-483
18. Lauder L, Ewen S, Azizi M, Mauri L, Lurz P, Lobo MD, Sharif F, Wijns W, Tsioufis C, Mahfoud F. Will spyral htn-off med change my practice? Spyral htn-off med: A prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. EuroIntervention. 2018;14:e603-e606
19. Koyama R, Mannic T, Ito J, Amar L, Zennaro MC, Rossier MF, Maturana AD. Microrna-204 is necessary for aldosterone-stimulated t-type calcium channel expression in cardiomyocytes. Int J Mol Sci. 2018;19
20. Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lepine C, Venisse A, Robidel E, Verkarre V, Meatchi T, Sibony M, Amar L, Bertherat J, de Reynies A, Londono-Vallejo A, Favier J, Castro-Vega LJ, Gimenez-Roqueplo AP. Telomerase activation and atrx mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2018
21. George MJ, Marks DJB, Rezk T, Breckenridge R, Sofat R, Martin J, MacAllister R, Touyz RM, Staessen JA, Bursztyn M, Lappin D, Barigou M, Hingorani A. Resistant hypertension: Trials and tribulations. Hypertension. 2018;71:772-780
22. Fernandes-Rosa FL, Daniil G, Orozco IJ, Goppner C, El Zein R, Jain V, Boulkroun S, Jeunemaitre X, Amar L, Lefebvre H, Schwarzmayr T, Strom TM, Jentsch TJ, Zennaro MC. A gain-of-function mutation in the clcn2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50:355-361
23. Faucon A-L, Bobrie G, Jannot A-S, Azarine A, Plouin P-F, Azizi M, Amar L. Cause of renal infarction. Journal of Hypertension. 2018;36:634-640
24. Ewen S, Lauder L, Azizi M, Kandzari DE, Pathak A, Sharif F, Wijns W, Mahfoud F, Luscher TF. Will spyral htn-on med change my practice? Spyral htn-on med: A prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. EuroIntervention. 2018;14:e598-e602
25. El Zein RM, Boulkroun S, Fernandes-Rosa FL, Zennaro MC. Molecular genetics of conn adenomas in the era of exome analysis. Presse Med. 2018;47:e151-e158
26. Denolle T, Menard J. [the urgent need for organisational changes of hypertension management in france]. Presse Med. 2018;47:839-841
27. Deborde T, Amar L, Bobrie G, Postel-Vinay N, Battaglia C, Tache A, Chedid A, Dhib MM, Chatellier G, Plouin PF, Burgun A, Azizi M, Jannot AS. Sex differences in antihypertensive treatment in france among 17 856 patients in a tertiary hypertension unit. J Hypertens. 2018;36:939-946
28. Courand PY, Azizi M, Lantelme P. Renal denervation in hypertension: Towards a true revival? Arch Cardiovasc Dis. 2018;111:541-544
29. Calsina B, Curras-Freixes M, Buffet A, Pons T, Contreras L, Leton R, Comino-Mendez I, Remacha L, Calatayud M, Obispo B, Martin A, Cohen R, Richter S, Balmana J, Korpershoek E, Rapizzi E, Deutschbein T, Vroonen L, Favier J, de Krijger RR, Fassnacht M, Beuschlein F, Timmers HJ, Eisenhofer G, Mannelli M, Pacak K, Satrustegui J, Rodriguez-Antona C, Amar L, Cascon A, Dolker N, Gimenez-Roqueplo AP, Robledo M. Role of mdh2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genet Med. 2018
30. Bulsei J, Darlington M, Durand-Zaleski I, Azizi M, Group DS. How to perform a cost-effectiveness analysis with surrogate endpoint: Renal denervation in patients with resistant hypertension (denerhtn) trial as an example. Blood Press. 2018;27:66-72
31. Buffet A, Morin A, Castro-Vega LJ, Habarou F, Lussey-Lepoutre C, Letouze E, Lefebvre H, Guilhem I, Haissaguerre M, Raingeard I, Padilla-Girola M, Tran T, Tchara L, Bertherat J, Amar L, Ottolenghi C, Burnichon N, Gimenez-Roqueplo AP, Favier J. Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier slc25a11 gene confer a predisposition to metastatic paragangliomas. Cancer Res. 2018;78:1914-1922
32. Buffet A, Burnichon N, Amar L, Gimenez-Roqueplo AP. Pheochromocytoma: When to search a germline defect? Presse Med. 2018;47:e109-e118
33. Bril A, Dolle L, Postel-Vinay N. S̩rie : Num̩rique et sant̩ Рavant-propos. Med Sci (Paris). 2018;34:448
34. Bouhanick B, Amar J, Amar L, Gosse P, Girerd X, Reznik Y, Mounier-Vehier C, Baguet JP, Boutouyrie P, Lepage B, Lantelme P, Chamontin B. Arterial stiffness evaluated by pulse wave velocity is not predictive of the improvement in hypertension after adrenal surgery for primary aldosteronism: A multicentre study from the french european society of hypertension excellence centres. Archives of Cardiovascular Diseases. 2018;111:564-572
35. Benoit C, Doubi-Kadmiri S, Benigni X, Crepin D, Riffault L, Poizat G, Vacher CM, Taouis M, Baroin-Tourancheau A, Amar L. Mirna long-term response to early metabolic environmental challenge in hypothalamic arcuate nucleus. Front Mol Neurosci. 2018;11:90
36. Baron S, Amar L, Faucon AL, Blanchard A, Baffalie L, Faucard C, Travers S, Pagny JY, Azizi M, Houillier P. Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. J Hypertens. 2018;36:1592-1601
37. Azizi M, Amar L, Lorthioir A. Resistant hypertension and obstructive sleep apnea: Is there a specific indication for endovascular renal denervation? Hypertension. 2018;72:281-282
38. Ashton EJ, Legrand A, Benoit V, Roncelin I, Venisse A, Zennaro MC, Jeunemaitre X, Iancu D, Van’t Hoff WG, Walsh SB, Godefroid N, Rotthier A, Del Favero J, Devuyst O, Schaefer F, Jenkins LA, Kleta R, Dahan K, Vargas-Poussou R, Bockenhauer D. Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies. Kidney Int. 2018;93:961-967
39. Antignac M, Diop IB, Macquart de Terline D, Kramoh KE, Balde DM, Dzudie A, Ferreira B, Houenassi MD, Hounsou D, Ikama MS, Kane A, Kimbally-Kaki SG, Kingue S, Kouam Kouam C, Limbole E, Mfeukeu Kuate L, Mipinda JB, N’Guetta R, Nhavoto C, Sesso Z, Sidy Ali A, Ali Toure I, Plouin PF, Perier MC, Narayanan K, Empana JP, Jouven X. Socioeconomic status and hypertension control in sub-saharan africa: The multination eight study (evaluation of hypertension in sub-saharan africa). Hypertension. 2018;71:577-584
40. Alhenc-Gelas F, Menard J. Is plasma renin activity genetically determined and how much does it matter for treating hypertension? Circ Genom Precis Med. 2018;11:e002139

2017

24. Azizi M. Catheter-based renal denervation for treatment of hypertension. Lancet. 2017;390:2124-2126.
25. Amar L, Sharabi Y, Rossi GP, Vidal-Petiot E, Dominiczak AF, Mulatero P, Faucon AL, Dhaun N, Touyz RM, Barigou M, Lorthioir A. Case of primary aldosteronism with discordant hormonal and computed tomographic findings. Hypertension. 2017;69:529-535.
26. Plouin PF, Baguet JP, Thony F, et al. High prevalence of multiple arterial bed lesions in patients with fibromuscular dysplasia: The ARCADIA registry (assessment of renal and cervical artery dysplasia). Hypertension. 2017;70:652-658.
27. Zennaro MC, Fernandes-Rosa F. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor mutations. J Endocrinol. 2017;234:T93-T106.
28. Zennaro MC, Boulkroun S, Fernandes-Rosa F. Genetic causes of functional adrenocortical adenomas. Endocr Rev. 2017;10.1210/er.2017-00189
29. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5:689-699.
30. Toledo RA, Burnichon N, Cascon A, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2017;13:233-247.
31. Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, Azizi M, Diaz-Cartelle J. Bipolar radiofrequency renal denervation with the vessix catheter in patients with resistant hypertension: 2-year results from the reduce-htn trial. J Hum Hypertens. 2017;31:366-368.
32. Seys E, Andrini O, Keck M, et al. Clinical and genetic spectrum of bartter syndrome type 3. J Am Soc Nephrol. 2017;28:2540-2552.
33. Postel-Vinay N, Bobrie G, Amar L, Goumet J, Bernard M. [text messaging and self-care support of hypertensive patients : First achievements]. Rev Med Suisse. 2017;13:1566-1569.
34. Oudijk L, Papathomas T, de Krijger R, Korpershoek E, Gimenez-Roqueplo AP, Favier J, Canu L, Mannelli M, Rapa I, Curras-Freixes M, Robledo M, Smid M, Papotti M, Volante M. Mtorc1 complex is significantly over-activated in sdhx-mutated paragangliomas. Neuroendocrinology. 2017;10.1159/000455864
35. Muller M, Ferlicot S, Guillaud-Bataille M, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in french fh mutation carriers. Clin Genet. 2017;10.1111/cge.13014
36. Moramarco J, El Ghorayeb N, Dumas N, Nolet S, Boulanger L, Burnichon N, Lacroix A, Elhaffaf Z, Gimenez Roqueplo AP, Hamet P, Bourdeau I. Pheochromocytomas are diagnosed incidentally and at older age in neurofibromatosis type 1. Clin Endocrinol (Oxf). 2017;86:332-339.
37. Monsuez JJ, Pham T, Karam N, Amar L, Chicheportiche-Ayache C, Menasche P, Desnos M, Dardel P, Weill I. Awareness of individual cardiovascular risk factors and self-perception of cardiovascular risk in women. Am J Med Sci. 2017;354:240-245.
38. Mathiesen JS, Habra MA, Bassett JHD, Choudhury SM, Balasubramanian SP, Howlett TA, Robinson BG, Gimenez-Roqueplo AP, Castinetti F, Vestergaard P, Frank-Raue K. Risk profile of the RET a883f germline mutation: An international collaborative study. J Clin Endocrinol Metab. 2017;102:2069-2074.
39. Martini AG, Xa LK, Lacombe MJ, Blanchet-Cohen A, Mercure C, Haibe-Kains B, Friesema ECH, van den Meiracker AH, Gross KW, Azizi M, Corvol P, Nguyen G, Reudelhuber TL, Danser AHJ. Transcriptome analysis of human reninomas as an approach to understanding juxtaglomerular cell biology. Hypertension. 2017;69:1145-1155.
40. Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future. Eur Heart J. 2017;38:3272-3281.
41. Lussey-Lepoutre C, Buffet A, Gimenez-Roqueplo AP, Favier J. Mitochondrial deficiencies in the predisposition to paraganglioma. Metabolites. 2017;7
42. Lebeault M, Pinson S, Guillaud-Bataille M, et al. Nationwide french study of ret variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid. 2017;10.1089/thy.2016.0399
43. Ladouceur M, Kachenoura N, Soulat G, Bollache E, Redheuil A, Azizi M, Delclaux C, Chatellier G, Boutouyrie P, Iserin L, Bonnet D, Mousseaux E. Impaired atrioventricular transport in patients with transposition of the great arteries palliated by atrial switch and preserved systolic right ventricular function: A magnetic resonance imaging study. Congenit Heart Dis. 2017;12:458-466.
44. Jouinot A, Assie G, Libe R, et al. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. J Clin Endocrinol Metab. 2017;102:923-932.
45. Hamdidouche I, Jullien V, Laurent S, Azizi M. Detecting nonadherence to antihypertensive treatment: Any time, anywhere? Hypertension. 2017;70:257-258.
46. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: From methodological issues to cardiovascular outcomes. J Hypertens. 2017;35:1133-1144.
47. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens. 2017;35:1891-1898.
48. Gravel G, Gimenez-Roqueplo AP, Halimi P. 68ga-dotatate pet/ct versus mri: Why the comparison of 68ga-dotatate pet/ct to an appropriate mri protocol is essential. J Nucl Med. 2017;58:184-185.
49. Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem JE, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi M, Mismetti P, Loriot MA. Interindividual variability in dabigatran and rivaroxaban exposure: Contribution of abcb1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15:273-283.
50. Gosse P, Cremer A, Pereira H, et al. Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation: The denerhtn study (renal denervation for hypertension). Hypertension. 2017;69:494-500.
51. Funder JW, Zennaro MC. 30 years of the mineralocorticoid receptor: The scientific impact of cloning the mineralocorticoid receptor: 30 years on. J Endocrinol. 2017;234:E3-E6.
52. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181-193.
53. Fernandes-Rosa FL, Boulkroun S, Zennaro MC. Somatic and inherited mutations in primary aldosteronism. J Mol Endocrinol. 2017;59:R47-R63.
54. Faucon AL, Bobrie G, Jannot AS, Azarine A, Plouin PF, Azizi M, Amar L. Cause of renal infarction: A retrospective analysis of 186 consecutive cases. J Hypertens. 2017;10.1097/HJH.0000000000001588
55. Courand PY, Pereira H, Del Giudice C, et al. Abdominal aortic calcifications influences the systemic and renal hemodynamic response to renal denervation in the DENERHTN (renal denervation for hypertension) trial. J Am Heart Assoc. 2017;6
56. Casas-Alba D, Vila Cots J, Monfort Carretero L, Martorell Sampol L, Zennaro MC, Jeunemaitre X, Camacho Diaz JA. Pseudohypoaldosteronism types i and ii: Little more than a name in common. J Pediatr Endocrinol Metab. 2017;30:597-601.
57. Calvet D, Amar L, Rossi GP, Laurent S, Dominiczak AF, Turc G, Jennings G, Guzik T, Touyz RM. Case of asymptomatic carotid artery stenosis in a hypertensive patient. Hypertension. 2017;69:985-991.
58. Burnichon N, Mazzella JM, Drui D, Amar L, Bertherat J, Coupier I, Delemer B, Guilhem I, Herman P, Kerlan V, Tabarin A, Wion N, Lahlou-Laforet K, Favier J, Gimenez-Roqueplo AP. Risk assessment of maternally inherited sdhd paraganglioma and phaeochromocytoma. J Med Genet. 2017;54:125-133.
59. Bulsei J, Darlington M, Durand-Zaleski I, Azizi M. How to perform a cost-effectiveness analysis with surrogate endpoint: Renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood Press. 2017;10.1080/08037051.2017.1394160:1-7.
60. Bahougne T, Imperiale A, Averous G, Chabrier G, Burnichon N, Gimenez-Roqueplo AP, Dali-Youcef N, Libe R, Baudin E, Roy C, Lang H, Kessler L. Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma. Endocr Relat Cancer. 2017;24:L7-L11.
61. Antignac M, Diop BI, Macquart de Terline D, et al. Fighting fake medicines: First quality evaluation of cardiac drugs in africa. Int J Cardiol. 2017;243:523-528.

2016

1. Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, Durieux P, Girerd X, Gosse P, Hernigou A, Herpin D, Houillier P, Jeunemaitre X, Joffre F, Kraimps JL, Lefebvre H, Menegaux F, Mounier-Vehier C, Nussberger J, Pagny JY, Pechere A, Plouin PF, Reznik Y, Steichen O, Tabarin A, Zennaro MC, Zinzindohoue F, Chabre O. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. Ann Endocrinol (Paris). 2016;77:179-186
2. Amar L, Lussey-Lepoutre C, Lenders JW, Djadi-Prat J, Plouin PF, Steichen O. Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: A systematic review and meta-analysis. Eur J Endocrinol. 2016;175:R135-145
3. Amrani-Midoun A, Kiando SR, Treard C, Jeunemaitre X, Bouatia-Naji N. The relationship between MTHFR C677T gene polymorphism and essential hypertension in a sample of an algerian population of oran city. Int J Cardiol. 2016;225:408-411
4. Azizi M, Pereira H, Hamdidouche I, Gosse P, Monge M, Bobrie G, Delsart P, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Girerd X, Michel Halimi J, Zannad F, Ormezzano O, Vaisse B, Herpin D, Ribstein J, Chamontin B, Mourad JJ, Ferrari E, Plouin PF, Jullien V, Sapoval M, Chatellier G. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial. Circulation. 2016;134:847-857
5. Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, Plouin PF, Steichen O. Sfe/sfhta/afce consensus on primary aldosteronism, part 4: Subtype diagnosis. Ann Endocrinol (Paris). 2016;77:208-213
6. Baudrand R, Gupta N, Garza AE, Vaidya A, Leopold JA, Hopkins PN, Jeunemaitre X, Ferri C, Romero JR, Williams J, Loscalzo J, Adler GK, Williams GH, Pojoga LH. Caveolin 1 modulates aldosterone-mediated pathways of glucose and lipid homeostasis. J Am Heart Assoc. 2016;5
7. Berra E, Azizi M, Capron A, Hoieggen A, Rabbia F, Kjeldsen SE, Staessen JA, Wallemacq P, Persu A. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297-306
8. Bourdeau I, Grunenwald S, Burnichon N, Khalifa E, Dumas N, Binet MC, Nolet S, Gimenez-Roqueplo AP. A sdhc founder mutation causes paragangliomas (pgls) in the french canadians: New insights on the SDHC-related PGL. J Clin Endocrinol Metab. 2016;101:4710-4718
9. Bruel A, Vargas-Poussou R, Jeunemaitre X, Labbe A, Merlin E, Bessenay L. [Gordon syndrome: The importance of measuring blood pressure in children]. Arch Pediatr. 2016;23:827-831
10. Burnichon N, Buffet A, Gimenez-Roqueplo AP. Pheochromocytoma and paraganglioma: Molecular testing and personalized medicine. Curr Opin Oncol. 2016;28:5-10
11. Castro-Vega LJ, Kiando SR, Burnichon N, Buffet A, Amar L, Simian C, Berdelou A, Galan P, Schlumberger M, Bouatia-Naji N, Favier J, Bressac-de Paillerets B, Gimenez-Roqueplo AP. The MITF, P.E318K variant, as a risk factor for pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2016;101:4764-4768
12. Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Favier J. Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene. 2016;35:1080-1089
13. Cornu E, Steichen O, Nogueira-Silva L, Kupers E, Pagny JY, Grataloup C, Baron S, Zinzindohoue F, Plouin PF, Amar L. Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism. Hypertension. 2016;68:989-994
14. Daniil G, Fernandes-Rosa FL, Chemin J, Blesneac I, Beltrand J, Polak M, Jeunemaitre X, Boulkroun S, Amar L, Strom TM, Lory P, Zennaro MC. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine. 2016;13:225-236
15. Faucon AL, Madjalian AM, Bobrie G, Amar L, Azizi M. [Towards new targets in the treatment of hypertension?]. Med Sci (Paris). 2016;32:861-866
16. Gravel G, Niccoli P, Rohmer V, Moulin G, Borson-Chazot F, Rousset P, Pasco-Papon A, Marcus C, Dubrulle F, Gouya H, Bidault F, Dupas B, Gabrillargues J, Caumont-Prim A, Hernigou A, Gimenez-Roqueplo AP, Halimi P. The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHX mutations carriers: A retrospective study on behalf of the PGL.EVA investigators. Eur Radiol. 2016;26:1696-1704
17. Kelly D, Rodzlan MR, Jeunemaitre X, Wall C. A novel mutation in KLHL3 gene causes familial hyperkalemic hypertension. QJM. 2016;109:487-488
18. Kiando SR, Tucker NR, Castro-Vega LJ, Katz A, D’Escamard V, Treard C, Fraher D, Albuisson J, Kadian-Dodov D, Ye Z, Austin E, Yang ML, Hunker K, Barlassina C, Cusi D, Galan P, Empana JP, Jouven X, Gimenez-Roqueplo AP, Bruneval P, Hyun Kim ES, Olin JW, Gornik HL, Azizi M, Plouin PF, Ellinor PT, Kullo IJ, Milan DJ, Ganesh SK, Boutouyrie P, Kovacic JC, Jeunemaitre X, Bouatia-Naji N. PHACTR1 is a genetic susceptibility locus for fibromuscular dysplasia supporting its complex genetic pattern of inheritance. PLoS Genet. 2016;12:e1006367
19. Ladouceur M, Redheuil A, Soulat G, Delclaux C, Azizi M, Patel M, Chatellier G, Legendre A, Iserin L, Boudjemline Y, Bonnet D, Mousseaux E. Longitudinal strain of systemic right ventricle correlates with exercise capacity in adult with transposition of the great arteries after atrial switch. Int J Cardiol. 2016;217:28-34
20. Lalli E, Barhanin J, Zennaro MC, Warth R. Local control of aldosterone production and primary aldosteronism. Trends Endocrinol Metab. 2016;27:123-131
21. Landau E, Amar L. Primary aldosteronism and pregnancy. Ann Endocrinol (Paris). 2016;77:148-160
22. Lepoutre-Lussey C, Thibault C, Buffet A, Morin A, Badoual C, Benit P, Rustin P, Ottolenghi C, Janin M, Castro-Vega LJ, Trapman J, Gimenez-Roqueplo AP, Favier J. From NF1 to SDHB knockout: Successes and failures in the quest for animal models of pheochromocytoma. Mol Cell Endocrinol. 2016;421:40-48
23. Lussey-Lepoutre C, Bellucci A, Morin A, Buffet A, Amar L, Janin M, Ottolenghi C, Zinzindohoue F, Autret G, Burnichon N, Robidel E, Banting B, Fontaine S, Cuenod CA, Benit P, Rustin P, Halimi P, Fournier L, Gimenez-Roqueplo AP, Favier J, Tavitian B. In vivo detection of succinate by magnetic resonance spectroscopy as a hallmark of SDHX mutations in paraganglioma. Clin Cancer Res. 2016;22:1120-1129
24. Mendes M, Dubourg J, Blanchard A, Bergerot D, Courand PY, Forni V, Frank M, Bobrie G, Menard J, Azizi M. Copeptin is increased in resistant hypertension. J Hypertens. 2016;34:2458-2464
25. Moramarco J, El Ghorayeb N, Dumas N, Nolet S, Boulanger L, Burnichon N, Lacroix A, Elhaffaf Z, Gimenez Roqueplo AP, Hamet P, Bourdeau I. Pheochromocytomas are diagnosed incidentally and at older age in neurofibromatosis type 1. Clin Endocrinol (Oxf). 2016
26. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, Damasceno A, Delles C, Gimenez-Roqueplo AP, Hering D, Lopez-Jaramillo P, Martinez F, Perkovic V, Rietzschel ER, Schillaci G, Schutte AE, Scuteri A, Sharman JE, Wachtell K, Wang JG. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The lancet commission on hypertension. Lancet. 2016;388:2665-2712
27. Persu A, Kjeldsen S, Staessen JA, Azizi M. Renal denervation for treatment of hypertension: A second start and new challenges. Curr Hypertens Rep. 2016;18:6
28. Persu A, Van der Niepen P, Touze E, Gevaert S, Berra E, Mace P, Plouin PF, Jeunemaitre X. Revisiting fibromuscular dysplasia: Rationale of the European fibromuscular dysplasia initiative. Hypertension. 2016;68:832-839
29. Plouin PF. Os 04-02 high prevalence of multisite fibromuscular dysplasia: The arcadia registry. J Hypertens. 2016;34 Suppl 1 – ISH 2016 Abstract Book:e55
30. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1-G10
31. Plouin PF, Fiquet B, Bobrie G, Jeunemaitre X. [Fibromuscular dysplasia of renal arteries]. Nephrol Ther. 2016;12 Suppl 1:S135-138
32. Postel-Vinay N, Bobrie G, Ruelland A, Oufkir M, Savard S, Persu A, Katsahian S, Plouin PF. Automated interpretation of home blood pressure assessment (HY-RESULT software) versus physician’s assessment: A validation study. Blood Press Monit. 2016;21:111-117
33. Postel-Vinay, N.; Bobrie, G.; Steichen, O.; Savard, S.; Persu, A.; Brouard, B.; Vegreville, M. Automated  interpretation of home blood pressure measurements with wireless blood pressure monitor and hy-result software : a user perception study
    Journal of Hypertension: September 2016 doi: 10.1097/01.hjh.0000491429.31435.d4
    http://journals.lww.com/jhypertension/Abstract/2016/09002/_OP_LB01_05__AUTOMATED_INTERPRETATION_OF_HOME.104.aspx
34. Reznik Y, Amar L, Tabarin A. Sfe/sfhta/afce consensus on primary aldosteronism, part 3: Confirmatory testing. Ann Endocrinol (Paris). 2016;77:202-207
35. Steichen O, Amar L, Chaffanjon P, Kraimps JL, Menegaux F, Zinzindohoue F. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery. Ann Endocrinol (Paris). 2016;77:220-225
36. Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J, Tops CM, Firth H, Dwight T, Ercolino T, Mannelli M, Opocher G, Clifton-Bligh R, Gimm O, Maher ER, Robledo M, Gimenez-Roqueplo AP, Dahia PL. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2016
37. Vouillarmet J, Fernandes-Rosa F, Graeppi-Dulac J, Lantelme P, Decaussin-Petrucci M, Thivolet C, Peix JL, Boulkroun S, Clauser E, Zennaro MC. Aldosterone-producing adenoma with a somatic KCNJ5 mutation revealing APC-dependent familial adenomatous polyposis. J Clin Endocrinol Metab. 2016;101:3874-3878
38. Zennaro MC, Jeunemaitre X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. Ann Endocrinol (Paris). 2016;77:214-219.

2015

1. Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, Loriot C, Elarouci N, Morin A, Menara M, Lepoutre-Lussey C, Badoual C, Sibony M, Dousset B, Libe R, Zinzindohoue F, Plouin PF, Bertherat J, Amar L, de Reynies A, Favier J, Gimenez-Roqueplo AP. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044Lussey-Lepoutre C, Bellucci A, Morin A, Buffet A, Amar L, Janin M, Ottolenghi C, Zinzindohoue F, Autret G, Burnichon N, Robidel E, Banting B, Fontaine S, Cuenod CA, Benit P, Rustin P, Halimi P, Fournier L, Gimenez-Roqueplo AP, Favier J, Tavitian B. In vivo detection of succinate by magnetic resonance spectroscopy as a hallmark of sdhx mutations in paraganglioma. Clin Cancer Res. 2015. Epub: 2015/10/23
2. Fernandes-Rosa FL, Amar L, Tissier F, Bertherat J, Meatchi T, Zennaro MC, Boulkroun S. Functional histopathological markers of aldosterone producing adenoma and somatic kcnj5 mutations. Mol Cell Endocrinol. 2015;408:220-226
3. Lefebvre H, Duparc C, Prevost G, Zennaro MC, Bertherat J, Louiset E. Paracrine control of steroidogenesis by serotonin in adrenocortical neoplasms. Mol Cell Endocrinol. 2015;408:198-204
4. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: From genetics to personalized medicine. Nat Rev Endocrinol. 2015;11:101-111
5. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (denerhtn): A multicentre, open-label, randomised controlled Lancet. 2015;385:1957-1965
6. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386:1588-1598
7. Azizi M, Pereira H, Bobrie G, Gosse P, Chatellier G. Renal denervation for resistant hypertension – authors’ reply. Lancet. 2015;386:1240
8. Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation. 2015;132:1825-1833
9. Mahfoud F, Bohm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Luscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the european clinical consensus conference for renal denervation: Considerations on future clinical trial design. Eur Heart J. 2015;36:2219-2227
10. Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E, Dubourg L, Monge M, Bergerot D, Baron S, Essig M, Bridoux F, Tack I, Azizi M. Indomethacin, amiloride, or eplerenone for treating hypokalemia in gitelman syndrome. J Am Soc Nephrol. 2015;26:468-475
11. Duparc C, Moreau L, Dzib JF, Boyer HG, Tetsi Nomigni M, Boutelet I, Boulkroun S, Mukai K, Benecke AG, Amar L, Gobet F, Meatchi T, Plouin PF, Zennaro MC, Louiset E, Lefebvre H. Mast cell hyperplasia is associated with aldosterone hypersecretion in a subset of aldosterone-producing adenomas. J Clin Endocrinol Metab. 2015;100:E550-560
12. Menara M, Oudijk L, Badoual C, Bertherat J, Lepoutre-Lussey C, Amar L, Iturrioz X, Sibony M, Zinzindohoue F, de Krijger R, Gimenez-Roqueplo AP, Favier J. Sdhd immunohistochemistry: A new tool to validate sdhx mutations in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab. 2015;100:E287-291
13. Nogueira-Silva L, Blanchard A, Curis E, Lorthioir A, Zhygalina V, Bergerot D, Baron S, Amar L, Bobrie G, Plouin PF, Menard J, Azizi M. Deciphering the role of vasopressin in primary aldosteronism. J Clin Endocrinol Metab. 2015;100:3297-3303
14. Carbone ML, Bregeon J, Devos N, Chadeuf G, Blanchard A, Azizi M, Pacaud P, Jeunemaitre X, Loirand G. Angiotensin ii activates the rhoa exchange factor arhgef1 in humans. Hypertension. 2015;65:1273-1278
15. Fernandes-Rosa FL, Giscos-Douriez I, Amar L, Gomez-Sanchez CE, Meatchi T, Boulkroun S, Zennaro MC. Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma. Hypertension. 2015;66:1014-1022
16. Lethielleux G, Amar L, Raynaud A, Plouin PF, Steichen O. Influence of diagnostic criteria on the interpretation of adrenal vein sampling. Hypertension. 2015;65:849-854
17. Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Pina IL, Stein K, Azizi M. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. 2015;65:5-15
18. Steichen O, Lorthioir A, Zinzindohoue F, Plouin PF, Amar L. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis. 2015;22:196-203
19. Zennaro MC, Boulkroun S, Fernandes-Rosa F. Inherited forms of mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab. 2015;29:633-645
20. Fadl Elmula FE, Jin Y, Yang WY, Thijs L, Lu YC, Larstorp AC, Persu A, Sapoval M, Rosa J, Widimsky P, Jacobs L, Renkin J, Petrak O, Chatellier G, Shimada K, Widimsky J, Kario K, Azizi M, Kjeldsen SE, Staessen JA. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263-274
21. Postel-Vinay N, Bobrie G, Ruelland A, Oufkir M, Savard S, Persu A, Katsahian S, Plouin PF. Automated interpretation of home blood pressure assessment (hy-result software) versus physician’s assessment: A validation study. Blood Press Monit. 2015
22. Okada T, Pellerin O, Savard S, Curis E, Monge M, Frank M, Bobrie G, Yamaguchi M, Sugimoto K, Plouin PF, Azizi M, Sapoval M. Eligibility for renal denervation: Anatomical classification and results in essential resistant hypertension. Cardiovasc Intervent Radiol. 2015;38:79-87
23. Amar L, Eisenhofer G. Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: Biochemistry versus imaging. Clin Endocrinol (Oxf). 2015;83:298-302
24. Amar L, Lorthioir A, Azizi M, Plouin PF. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. Eur J Endocrinol. 2015;172:R125-129
25. Boulkroun S, Fernandes-Rosa FL, Zennaro MC. Molecular and cellular mechanisms of aldosterone producing adenoma development. Front Endocrinol (Lausanne). 2015;6:95
26. Zennaro MC, Fernandes-Rosa F, Boulkroun S, Jeunemaitre X. Bilateral idiopathic adrenal hyperplasia: Genetics and beyond. Horm Metab Res. 2015;47:947-952
27. Kjeldsen SE, Persu A, Azizi M. Design of renal denervation studies not confounded by antihypertensive drugs. J Am Soc Hypertens. 2015;9:337-340
28. Zennaro MC, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol. 2015;224:R63-77
29. Beaussier H, Boutouyrie P, Bobrie G, Frank M, Laurent S, Coudore F, Azizi M. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015;33:2526-2533
30. Camelli S, Bobrie G, Postel-Vinay N, Azizi M, Plouin PF, Amar L. Lb01.11: Prevalence of secondary hypertension in young hypertensive adults. J Hypertens. 2015;33 Suppl 1:e47
31. Hamdidouche I, Jullien V, Billaud EM, Boutouyrie P, Azizi M, Laurent S. 7b.06: Routine urinary detection of antihypertensive drugs for estimation of adherence to treatment: A cross sectional study. J Hypertens. 2015;33 Suppl 1:e93
32. Khettab H, Lorthior A, Niarra R, Chambon Y, Jeunemaitre X, Plouin PF, Laurent S, Boutouyrie P, Azizi M. 6d.03: Flow-mediated dilatation (fmd) and endothelium-independent dilatation (eid) in patients with multifocal fibromuscular dysplasia: A cross-sectional study. J Hypertens. 2015;33 Suppl 1:e82-83
33. Kiando S, Plouin PF, Barlassina MC, Cusi D, Galan P, Lathrop M, Jeunemaitre X, Bouatia-Naji N. 6c.02: Exome sequencing in seven families and gene-based association studies support genetic heterogeneity and suggest possible candidates for fibromuscular dysplasia. J Hypertens. 2015;33 Suppl 1:e79
34. Kiando SR, Barlassina C, Cusi D, Galan P, Lathrop M, Plouin PF, Jeunemaitre X, Bouatia-Naji N. Exome sequencing in seven families and gene-based association studies indicate genetic heterogeneity and suggest possible candidates for fibromuscular dysplasia. J Hypertens. 2015;33:1802-1810; discussion 1810
35. Mirault T, Pernot M, Frank M, Couade M, Niarra R, Azizi M, Emmerich J, Jeunemaitre X, Fink M, Tanter M, Messas E. Carotid stiffness change over the cardiac cycle by ultrafast ultrasound imaging in healthy volunteers and vascular ehlers-danlos syndrome. J Hypertens. 2015;33:1890-1896; discussion 1896
36. Ogna VF, Pereira E, Sapoval M, Azizi M. 4a.07: Prevalence and risk factors for refractory hypertension in the denerhtn study. J Hypertens. 2015;33 Suppl 1:e51
37. Picard HL, Latreche S, Thurairajasingam N, Auzan C, Fiquet B, Frayssinet R, Garnier A, Jendruchova V, Lobbedez T, Martorell L, Mortier G, Pela I, Taque S, Vargas-Poussou R, Clauser E, Jeunemaitre X. 6c.01: Cullin-3 mutations leading to skipping of exon 9 are responsible for severe cases of familial hyperkalaemic hypertension. J Hypertens. 2015;33 Suppl 1:e79
38. Picard HL, Thurairajasingam N, Decramer S, Girerd X, Oshaugnessy K, Mulatero P, Roussey G, Tack I, Unwin R, Vargas-Poussou R, Jeunemaitre X. 1a.01: Mutations affecting the conserved acidic motif of wnk1 cause inherited normotensive hyperkalemic acidosis. J Hypertens. 2015;33 Suppl 1:e1
39. Vinay NP, Bobrie G, Ruelland A, Oufkir M, Savard S, Persu A, Katsahian S, Plouin PF. Lb03.06: Automated interpretation of home blood pressure assessment (hy-result(r) software) versus physician’s assessment. A validation study. J Hypertens. 2015;33 Suppl 1:e127
40. Zennaro MC, Fernandes-Rosa F, Boulkroun S. [genetic alterations in primary aldosteronism]. Med Sci (Paris). 2015;31:389-396
41. Sacre K, Escoubet B, Zennaro MC, Chauveheid MP, Gayat E, Papo T. Overweight is a major contributor to atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease: A cross-sectional controlled study. Medicine (Baltimore). 2015;94:e2177
42. Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, Hopkins PN, Brown N, Raby BA, Lasky-Su J, Adler GK, Cui J, Guo X, Taylor KD, Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Pojoga LH. A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in caucasians and hispanics. Metabolism. 2015;64:1674-1681
43. Amar L. [primary aldosteronism]. Rev Prat. 2015;65:817-821
44. Plouin PF. [why look for secondary hypertension?]. Rev Prat. 2015;65:807-809
45. Bagula A, Castelli L, Zennaro M. On the design of smart parking networks in the smart cities: An optimal sensor placement model. Sensors (Basel). 2015;15:15443-15467
46. Jaulent MC, Assele-Kama A, Savard S, Giavarini A, Touze E, Jeunemaitre X, Ugon A, Plouin PF, Toubiana L. Building a semantic interoperability framework for care and research in fibromuscular dysplasia. Stud Health Technol Inform. 2015;216:217-221
47. Toubiana L, Ugon A, Giavarini A, Riquier J, Charlet J, Jeunemaitre X, Plouin PF, Jaulent MC. A « pivot » model to set up large scale rare diseases information systems: Application to the fibromuscular dysplasia registry. Stud Health Technol Inform. 2015;210:887-891
48. Duclos M, Dejager S, Postel-Vinay N, di Nicola S, Quere S, Fiquet B. Physical activity in patients with type 2 diabetes and hypertension–insights into motivations and barriers from the mobile study. Vasc Health Risk Manag. 2015;11:361-371

2014

1. Amar L, Lorthioir A, Giavarini A, Plouin PF, Azizi M. Reconnaître, évaluer et prendre en charge une hypertension artérielle d’origine surrénale. Presse Med 2014;43:420-7
2. Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, Satoh F, Young WF Jr, Rossi GP.Response to implementation of rapid cortisol during adrenal vein sampling.Hypertension 2014;63:e89
3. Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Ménard J,Plouin PF. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for LVM regression in patients with resistant hypertension. J Hypertens 2014;32:2038-44
4. Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques P, Llorens-Cortes C.randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase A inhibitor prodrug. ClinPharmacokinet 2014;53:385-95
5. Balcarek J, Seva Pessoa B, Bryson C, Azizi M, Menard J, Garrelds IM, McGeehan G, Reeves RA, Griffith SG, Danser AH, Gregg R. Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension 2014;63:942-50
6. Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Samson-Couterie B, Zennaro MC, Plouin PF, Skah S, Plateroti M, Lefèbvre H, Sahut-Barnola I, Batisse-Lignier M, Assié G, Lefrançois-Martinez AM, Bertherat J, Martinez A, Val P. WNT/β-catenin signalling is activated in aldosterone producing adenomas and controls aldosterone production. Hum Mol Genet 2014;23:889-905
7. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, Cohen DJ, Matsumoto AH, Steffes M, Jaff MR, Prince MR, Lewis EF, Tuttle KR, Shapiro JI, Rundback JH, Massaro JM, D’Agostino RB Sr, Dworkin LD; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:13-22
8. Denolle T, Azizi M, Massart C, Zennaro MC. [Itraconazole: a new drug-related cause of hypertension]. Ann CardiolAngeiol (Paris) 2014;63:213-5
9. Giavarini A, Savard S, Sapoval M, Plouin PF, Steichen O. Clinical management of renal artery fibromuscular dysplasia: temporal trends and outcomes. J Hypertens2014;32:2433-8
10. Nguyen G, Blanchard A, Curis E, Bergerot D, Chambon Y, Hirose T, Caumont-Prim A, Tabard SB, Baron S, Frank M, Totsune K, Azizi M. Plasma soluble (pro)renin receptor is independent of plasma renin, prorenin, and aldosterone concentrations but is affected by ethnicity. Hypertension 2014;63:297-302
11. Persu A, Azizi M, Jin Y, Volz S, Rosa J, FadlElmula FE, Pechere-Bertschi A, Burnier M, Mark PB, Elvan A, Renkin J, Sapoval M, Kahan T, Kjeldsen S, Staessen JA. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens 2014;32:2422-7
12. Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, Barral X, Jeunemaitre X, Morganti A, Plouin PF, de Leeuw P. European consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014;32:1367-78
13. Persu A, Januszewicz A, Morganti A, Plouin PF, de Leeuw P. Diagnosis and management of fibromuscular dysplasia. J Hypertens 2014;32:2098-9
14. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, Severino F, Rosa J, Adiyaman A, FadlElmula FE, Taylor A, Pechere-Bertschi A, Wuerzner G, Jokhaji F, Kahan T, Renkin J, Monge M, Widimsky P, Jacobs L, Burnier M, Mark PB, Kjeldsen SE, Andersson B, Sapoval M, Staessen JA. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014;28:150-6
15. Persu A, Sapoval M, Azizi M, Monge M, Danse E, Hammer F, Renkin J. Renal artery stenosis following renal denervation: a matter of concern. J Hypertens 2014;32:2101-5
16. Plouin PF, Amar L, Azizi M. Dilatation des sténoses athéroscléreuses des artères rénales : la fin de l’histoire ? Rev Med Intern 2014;35:697-9
17. Postel-Vinay N, Bobrie G, Steichen O, Sosner P, Baguet JP, Gosse P, Plouin PF. HY-QUEST – Standardised patient questionnaire to be completed at home before a first visit for hypertension. A validation study in specialisedcentres in France. J Hypertens 2014;32:693-8
18. Postel-Vinay N, Hanon O, Clerson P, Brown JM, Ménard J, Paillaud E, Alonso E, Pasquier F, Pariel S, Belliard S, Péré JJ, Belmin J. Validation of the Test Your Memory (F-TYM Test) in a French memory clinic population.ClinNeuropsychol 2014;28:994-1007
19. Rafat C, Bobrie G, Chedid A, Nochy D, Hernigou A, Plouin PF. Sarcoidosis presenting as severe renin-dependent hypertension due to kidney vascular injury. Clin Kidney J 2014;7: 383-6
20. Rafat C, Zinzindohoue F, Hernigou A, Hignette C, Favier J, Tenenbaum F, Gimenez-Roqueplo AP, Plouin PF, Amar L. Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery. J ClinEndocrinolMetab 2014;99:E2681-5
21. Rossi GP, Auchus R, Brown M, Lenders JWM, Naruse M, Plouin PF, Satoh F, Young WF. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014;63:151-60
22. Sapoval M, Azizi M. Renal artery denervation for the treatment of resistant hypertension. Update after Medtronic announcement that its Symplicity HTN3 study failed to meet its primary efficacy end point. DiagnInterv Imaging 2014;95:353-4
23. Steichen P, Plouin PF. Prise en charge actuelle de l’hypertension artérielle. Rev Med Intern 2014;35:235-42

2013

1. Amar L, Azizi M, Ménard J, Peyrard S, Plouin PF. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens 2013;31:624-9
2. Amar L, Savard S, Steichen O, Azizi M, Plouin PF. Classification de la dysplasie fibromusculaire des artères rénales en deux types angiographiques : concordances cliniques. J Mal Vasc 2013; 38:115-6
3. Azizi M, Amar L, Ménard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant 2013;28:36-43
4. Azizi M, Blanchard A, Charbit B, Wuerzner G, Peyrard S, Ezan E, Funck-Brentano C,Menard J: Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Hypertension 2013;61: 1239-45
5. Azizi M, Menard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther 2013;38: 832-40
6. Azizi M, Monge M, Lorthioir A, Bobrie G, Amar L. Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. J Hypertens 2013;31: 1948-51
7. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013;45:440-4
8. Blanchard A, Steichen O, De Mota N, Curis E, Gauci C, Frank M, Wuerzner G, Kamenicky P, Passeron A, Azizi M, Llorens-Cortes C: An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. J Clin Endocrinol Metab 2013;98: 2084-9
9. Boulkroun S, Golib Dzib JF, Samson-Couterie B, Rosa FL, Rickard AJ, Meatchi T, Amar L, Benecke A, Zennaro MC. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Mol Cell Endocrinol 2013;371:221-7
10. Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M,Gaussem P: Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis 2013;12: 661-75.
11. Giavarini A, Chedid A, Bobrie G, Plouin PF, Hagège A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart 2013;99:1438-44
12. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F, Cardot-Bauters C, Delemer B, Chabolle F, Coupier I, Libé R, Peitzsch M, Peyrard S, Tenenbaum F, Plouin PF, Chatellier G, Rohmer V. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA investigators. J Clin Endocrinol Metab 2013; 98:E162-73
13. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E; for the French group of Endocrine and Adrenal tumors (GTE –RENATEN and COMETE networks). One-year progression-free survival of therapy-naïve patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013 98:4006-12
14. Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, Buffet A, Marcaillou C, Bertherat J, Amar L, Rustin P, De Reyniès A, Gimenez-Roqueplo AP, Favier J. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013;23:739-52
15. Monge M, Lorthioir A, Bobrie G, Azizi M. New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension. J Renin Angiotensin Aldosterone Syst 2013;14:285-9
16. Monge M, Lorthioir A, Bobrie G, Briet M, Plouin PF, Sapoval M, Azizi M. Endovascular renal nerve ablation as a treatment for resistant hypertension. J Mal Vasc 2013;38:367-72
17. Persu A, Azizi M, Burnier M, Staessen JA. Residual effect of renal denervation in patients with truly resistant hypertension. Hypertension 2013;62: 450-2
18. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013;62:331-6
19. Savard S, Azarine A, Jeunemaitre X, Azizi M, Plouin PF, Steichen O. Association of smoking with phenotype at diagnosis and vascular interventions in patients with renal artery fibromuscular dysplasia. Hypertension 2013;61:1227-32
20. Vidal-Trecan T, El Batti S, Plouin PF, Sapoval M, Fichelle JM, Fabiani JN. Hypertension artérielle rénovasculaire sévère : traitement par angioplastie aortique et autotransplantation du rein. J Mal Vasc 2013;38:131-2

Syndrome de Conn : Nouvelles pistes génétiques (Nature Genetics Février 2013)  Présentation 

2012

1. Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet Guignat L, Drui D, Chupin M, Josseaume J, Affres H, Plouin PF, Bertherat J, Jeunemaître X, Gimenez-Roqueplo AP. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab 2012;97:E805-9
2. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma.  Horm Metab Res 2012;44:385-9
3. Azizi M, Steichen O, Frank M, Bobrie G, Plouin PF, Sapoval M. Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg 2012;43:293-9
4. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective randomized open blinded end point study in a tertiary referral centre. J Hypertension 2012
5. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G, Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M, Pilon C, Plouin PF, Rayes N, Seccia TM, Veglio F, Williams TA, Zinnamosca L, Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro MC. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012;59:592-8
6. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M, Travers C, Simian C, Burnichon N, Abermil N, Favier J, Jeunemaitre X, Gimenez-Roqueplo AP. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012; 44(5):359-66.
7. Burnichon N, Cascon A, Schiavi F, Paes Morales N, Comino-Mendez I, Abermil N, Inglada-Perez L, de Cubas AA, Amar L, Barontini MB, Bernaldo de Quiros S, Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD, Corssmit EP, Giacche M, de Krijger RR, Ercolino T, Girerd X, Gomez-Garcia EB, Gomez-Grana A, Guilhem I, Hes F, Honrado E, Korpershoek E, Lenders JW, Leton R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops C, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012;18:2828-37
8. Favier J, Igaz P, Burnichon N, Amar L, Libé R, Badoual C, Tissier F, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol 2012;23:34-42
9. Harakalova M, van der Smagt J, de Kovel CG, Van’t Slot R, Poot M, Nijman IJ, Medic J, Joziasse I, Deckers J, Roos-Hesselink JW, Wessels MW, Baars HF, Weiss MM, Pals G, Golmard L, Jeunemaitre X, Lindhout D, Cuppen E, Baas AF. Incomplete segregation of MYH11 variants with thoracic aortic aneurysms and dissections and patent ductus arteriosus. Eur J Hum Genet. 2012 Sep 12. doi: 10.1038/ejhg.2012.206.
10. Lahlou-Laforêt K, Consoli SM, Jeunemaitre X, Gimenez-Roqueplo AP. Presymptomatic genetic testing in minors at risk of paraganglioma and pheochromocytoma: our experience of oncogenetic multidisciplinary consultation. Horm Metab Res. 2012; 44(5):354-8.
11. Lepoutre-Lussey C, Rousseau A, Al Ghuzlan A, Amar L, Hignette C, Cioffi A, Zinzindohoué F, Leboulleux S, Plouin PF. Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional composite tumor. Eur J Endocrinol 2012;166:131-5
12. Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libé R, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP, Favier J. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 2012 Apr 4. [Epub ahead of print]
13. Louis-Dit-Picard H, Barc J,  Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Isnard Bagnis C, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M, International Consortium for Blood Pressure (ICBP), Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet. 2012; 44:456-60, S1-3.
14. Luong Nguyen LB, Warzocha U, Brillet PY, Abad S, Larroche C, Amar L, Frachet B, Dhote R. [Vascular involvement in Cogan’s syndrome. A case report.]. J Mal Vasc 2012;37:19-21
15. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M. KCNJ5 Mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012;59:235-40
16. Persu A, Touzé E, Mousseaux E, Barral X, Joffre F, Plouin PF. Diagnosis and management of fibromuscular dysplasia: an expert consensus. Europ J Clin Invest 2012;42:338-47
17. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2012;44:390-9
18. Rao AD, Sun B, Saxena A, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams JS. Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. J Hum Hypertens. 2012 May 31. [Epub ahead of print]
19. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012;97:1606-14
20. Salem JE, Bruguière E, Iserin L, Guiochon-Mantel A,  Plouin PF. Hypertension and aortorenal disease in Alagille syndrome. J Hypertens 2012 [in press]
21. Salvi E, Kutalik Z, Glorioso N, Benaglio P, Frau F, Kuznetsova T, Arima H, Hoggart C, Tichet J, Nikitin YP, Conti C, Seidlerova J, Tikhonoff V, Stolarz-Skrzypek K, Johnson T, Devos N, Zagato L, Guarrera S, Zaninello R, Calabria A, Stancanelli B, Troffa C, Thijs L, Rizzi F, Simonova G, Lupoli S, Argiolas G, Braga D, D’Alessio MC, Ortu MF, Ricceri F, Mercurio M, Descombes P, Marconi M, Chalmers J, Harrap S, Filipovsky J, Bochud M, Iacoviello L, Ellis J, Stanton AV, Laan M, Padmanabhan S, Dominiczak AF, Samani NJ, Melander O, Jeunemaitre X, Manunta P, Shabo A, Vineis P, Cappuccio FP, Caulfield MJ, Matullo G, Rivolta C, Munroe PB, Barlassina C, Staessen JA, Beckmann JS, Cusi D. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension. 2012; 59(2):248-55.
22. Sapoval M, Azizi A, Bobrie G, Cholley B, Pagny JY, Plouin PF. Endovascular renal artery denervation. Why, when and how? CIVR [in press]
23. Savard S, Steichen O, Azarine A, Azizi M, Jeunemaitre X, Plouin PF. Association Between Two Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics. Circulation. 2012;126(25):3062-9.
24. Savoldelli V, Gillaizeau F, PouchotJ,Postel-VinayN,Plouin PF, Durieux P, Sabatier B. Validation of a French version of the 8-item Morisky Medication Adherence Scale in hypertensive adults. J Clin Hypertension 2012
25. Steichen O, Sapoval M, Frank M, Bobrie G, Plouin PF, Azizi M. Dénervation rénale endovasculaire par radiofréquence dans l’hypertension artérielle résistante. Presse Med 2012;41:349–57
26. Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Hormone Met Res 2011;44:221-7
27. Sun B, Chamarthi B, Williams JS, Krug AW, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH. Different polymorphisms of the mineralocorticoid receptor gene are associated with either glucocorticoid or mineralocorticoid levels in hypertension. J Clin Endocrinol Metab. 2012 Sep;97(9):E1825-9
28.  Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK. Abnormal Aldosterone Physiology and Cardiometabolic Risk Factors. Hypertension. 2013 Feb 11
29. Vidal-Petiot E, Cheval L, Faugeroux J, Malard T, Doucet A, Jeunemaitre X, Hadchouel J. A new methodology for quantification of alternatively spliced exons reveals a highly tissue-specific expression pattern of WNK1 isoforms. PLoS One. 2012;7(5):e37751.
30. van der Linden P, Steichen O, Zinzindohoué F, Plouin PF. Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study. J Hypertens 2012;30: 761-9
31. Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Ida Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Shi Y. Lysine-Specific Demethylase 1: An Epigenetic Regulator of Salt-Sensitive Hypertension. Am J Hypertens. 2012 Apr 26. doi: 10.1038/ajh.2012.43

2011

1. Amar L, Azarine A, Carreira E, Vidal-Trécan T, Plouin PF. Dysplasie des artères rénales chez l’adulte. Presse Med 2011;40:720-5
2. Azizi M, Frank M, Steichen O, Blanchard A. [Advantages and limitations of renin inhibition with aliskiren]. Ann Pharm Fr 2011;69:142-50
3. Bergaya S, Faure S, Baudrie V, Rio M, Escoubet B, Bonnin P, Henrion D, Loirand G, Achard JM, Jeunemaitre X, Hadchouel J. WNK1 regulates vasoconstriction and blood pressure response to alpha 1-adrenergic stimulation in mice. Hypertension. 2011; 58(3):439-45.
4. Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, Azizi M. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol. 2011; 6:753-9
5. Boulkroun S, Samson-Couterie B, Golib-Dzib JF, Amar L, Plouin PF, Sibony M, Lefebvre H, Louiset E, Jeunemaitre X, Meatchi T, Benecke A, Lalli E, Zennaro MC. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology 2011;152:4753-63
6. Burnichon N, Lepoutre-Lussey C, Laffaire J, Gadessaud N, Molinié V, Hernigou A, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur J Endocrinol 2011;164:141-5
7. Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytomas and paragangliomas. Hum Mol Genet 2011;15:3974-85
8. Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011; 20(20):3974-85.
9. Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, Jeunemaitre X, Thomas A. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am J Hypertens. 2011; 24(10):1143-8
10. Hubert EL, Teissier R, Fernandes-Rosa FL, Fay M, Rafestin-Oblin ME, Jeunemaitre X, Metz C, Escoubet B, Zennaro MC. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol. 2011; 22(11):1997-2003.
11. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, Morris RW, Tzoulaki I, O’Brien ET, Poulter NR, Sever P, Shields DC, Thom S, Wannamethee SG, Whincup PH, Brown MJ, Connell JM, Dobson RJ, Howard PJ, Mein CA, Onipinla A, Shaw-Hawkins S, Zhang Y, Smith GD, Day IN, Lawlor DA, Goodall AH; The Cardiogenics Consortium, Fowkes FG, Abecasis GR, Elliott P, Gateva V; The Global BPgen Consortium, Braund PS, Burton PR, Nelson CP, Tobin MD, van der Harst P, Glorioso N, Neuvrith H, Salvi E, Staessen JA, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P, Org E, Putku M, Sõber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle DS, Hastie CE, Hedner T, Lee WK, Melander O, Wahlstrand B, Hardy R, Wong A, Cooper JA, Palmen J, Chen L, Stewart AF, Wells GA, Westra HJ, Wolfs MG, Clarke R, Franzosi MG, Goel A, Hamsten A, Lathrop M, Peden JF, Seedorf U, Watkins H, Ouwehand WH, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes MV, Kivimaki M, Shah S, Shah T, Talmud PJ, Whittaker J, Wallace C, Delles C, Laan M, Kuh D, Humphries SE, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L, Stanton AV, Dominiczak AF, Farrall M, Hingorani AD, Samani NJ, Caulfield MJ, Munroe PB. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011;89:688-700
12. Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WNM, Gimenez-Roqueplo AP, de Krijger RR. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011;96:E1472-6
13. Pasquini M, Trystram D, Oppenheim C, Plouin PF, Touzé E. Dysplasie fibromusculaire cervicale et intracrânienne. Presse Med 2011;40:713-9
14. Pojoga LH, Underwood PC, Goodarzi MO, Williams JS, Adler GK, Jeunemaitre X, Hopkins PN, Raby BA, Lasky-Su J, Sun B, Cui J, Guo X, Taylor KD, Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH. Variants of the caveolin-1 gene: a translational investigation linking insulin resistance and hypertension. J Clin Endocrinol Metab. 2011; 96(8):E1288-92.
15. Steichen O, Blanchard A, Plouin PF. Assessment of the serum sodium to urinary sodium divided by (serum potassium)² to urinary potassium as a screening tool for primary aldosteronism. Europ J Clin Invest 2011;41:189-94
16. Sun B, Williams JS, Pojoga L, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Ferri C, Williams GH. Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses. J Renin Angiotensin Aldosterone Syst. 2011; 12(4):564-71.
17. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines (CPG), Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu B, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Kolh P, Torbicki A, Agewall S, Blinc A, Bulvas M, Cosentino F, De Backer T, Gottsäter A, Gulba D, Guzik TJ, Jönsson B, Késmárky G, Kitsiou A, Kuczmik W, Larsen ML, Madaric J, Mas JL, McMurray JJ, Micari A, Mosseri M, Müller C, Naylor R, Norrving B, Oto O, Pasierski T, Plouin PF, Ribichini F, Ricco JB, Ruilope L, Schmid JP, Schwehr U, Sol BG, Sprynger M, Tiefenbacher C, Tsioufis C, Van Damme H. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J 2011;32:2851-906
18. Underwood PC, Sun B, Williams JS, Pojoga LH, Raby B, Lasky-Su J, Hunt S, Hopkins PN, Jeunemaitre X, Adler GK, Williams GH. The association of the angiotensinogen gene with insulin sensitivity in humans: a tagging single nucleotide polymorphism and haplotype approach Metabolism. 2011; 60(8):1150-7
19. Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. J Hypertens. 2011; 29(10):1913-8
20. Zhang Y, Shen J, He X, Zhang K, Wu S, Xiao B, Zhou X, Phillips RS, Gao P, Jeunemaitre X, Zhu D. A rare variant at the KYNU gene is associated with kynureninase activity and essential hypertension in the Han Chinese population. Circulation Cardiovasc Genet. 2011; 4(6):687-94

2010

1. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699. A proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56:831-8
2. Amar L, Lepoutre C, Bobrie G, Plouin PF. Hypertension endocrine. Rev Med Interne 2010;31:697-704
3. Amar L, Plouin PF, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis 2010;5:9
4. Boulkroun S, Samson-Couterie B, Golib Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin PF, Lalli E, Jeunemaitre X, Benecke A, Meatchi T, Zennaro MC. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010;56:885-92
5. Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011-20.
6. Consoli SM, Lemogne C, Roch B, Laurent S, Plouin PF, Lane RD. Differences in emotion processing in patients with essential and secondary hypertension. Am J Hypertens 2010;23:515-21
7. Elvira-Matelot E, Zhou X, Farman N, Beaurain G, Henrion-Caude A, Hadchouel J and Jeunemaitre X. Regulation of WNK1 by miR-192, a kidney-specific microRNA whose expression is modulated by aldosterone. J Am Soc Nephrol  2010; 21; 1724-1731.
8. Frank M, Peyrard S, Bobrie G, Azizi M. Method of mean value calculation as an additional source of variability in ambulatory blood pressure measurement. Am J Hypertens 2010 23:725-31
9. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, de Krijger RR, Gimenez-Roqueplo AP, Dinjens WNM. IDH mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2010;95:1274-8
10. Fiessinger JN, Postel-Vinay N, Bobrie G. Recommendations pour l’automesure tensionnelle. Bull Acad Natl Med. 2010;194:663-6
11. Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, Grand G, Buclin T. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Europ J Endocrinol 2010;162:951-60
12. Hadchouel J, Soukaseum C, Büsst C, Zhou XO, Baudrie V, Zürrer T, Cambillau M, Elghozi JL, Lifton RP, Loffing J, Jeunemaitre X. Decreased ENaC expression compensates the increased NCC activity following inactivation of the kidney-specific isoform of WNK1 and prevents hypertension. Proc Natl Acad Sci U S A. 2010 ;107:18109-14
13. Lepoutre-Lussey C, Plouin PF, Steichen O. Cardiovascular risk factors in hypertensive patients born in Northern Africa and living in France. Blood Press 2010;19:75-80
14. Manolopoulou J, Gerum S, Mulatero P, Rossignol P, Plouin PF, Reincke M, Bidlingmaier M. Salivary aldosterone as a diagnostic aid in primary aldosteronism. Horm Metab Res 2010;42:400-5
15. Plouin PF, Bax L. Diagnosis and treatment of renal artery stenosis. Nat Rev Nephrol 2010;6:151-9
16. Sosner P, Plouin PF, Herpin D. Urgences hypertensives de l’adulte. Presse Med 2010;39:1026-31
17. Steichen O, Amar L, Plouin PF. Primary stenting for atherosclerotic renal artery stenosis. J Vasc Surg 2010;51:1574-80
18. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9
19. Thouënnon E, Pierre A, Tanguy Y, Guillemot J, Manecka D, Guérin M, Ouafik L, Muresan M, Klein M, Bertherat J, Lefebvre H, Plouin PF, Yon L, Anouar Y. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocr Relat Cancer 2010;17:637-51
20. Touzé E, Oppenheim C, Trystram D, Nokam G, Pasquini M, Alamowitch S, Hervé D, Garnier P, Mousseaux E, Plouin PF. Fibromuscular dysplasia of cervical and intracranial arteries. Int J Stroke 2010; 5:296-305
21. Trinquart L, Mounier-Vehier C, Sapoval M, Gagnon N, Plouin PF. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 2010;56:525-32
22. Underwood PC, Sun B, Williams JS, Pojoga LH, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams GH. The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study. J Clin Endocrinol Metab. 2010; 95(9):E75-9
23. van Leeuwen N*, Caprio M*, Blaya C, Fumeron F, Sartorato P, Ronconi V, Giacchetti G, Mantero F, Fernandes-Rosa FL, Simian C, Peyrard S, Zitman FG, de Kloet R, Azizi M, Jeunemaitre X, DeRijk RH, Zennaro MC. The functional -2G variant of the mineralocorticoid receptor modulates blood pressure, renin and aldosterone levels. Hypertension 2010 ; 56 :995-1002.
24. Watkins WS, Hunt SC, Williams GH, Tolpinrud W, Jeunemaitre X, Lalouel JM, Jorde LB. Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: the importance of haplotypes. J Hypertension 2010; 28(1):65-75.

2009

1. Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009;41:687-96
2. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ, Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH, Pattynama PM, van de Ven PJ, Vroegindeweij D, Kroon AA, de Haan MW, Postma CT, Beutler JJ. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009;150:840-8
3. Bertherat J, Arlt W, Beuschlein F, Chanson P, Mantero F, Plouin PF. Adrenal tumours and hormone excess. Ann Endocrinol (Paris) 2009;70:147
4. Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Cascon A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, Rückauer K, Plouin PF, Darrouzet V, Giraud S, Eng C, Neumann HP. Head and neck paragangliomas in Von Hippel-Lindau disease and Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 2009;94: 1938-44
5. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet v, Niccoli P, Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, Bertherat J, Wion-Barbot N, Murat A, Vénisse A, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP for the PGL.NET network. SDH genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009;94:2817-27
6. Favier J, Brière JJ, Burnichon N, Rivière J, Vescovo L, Benit P, Giscos-Douriez I, De Reyniès A, Bertherat J, Badoual C, Tissier F, Amar L, Libé R, Plouin PF, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 2009;4:e7094
7. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H. Metoclopramide stimulates catecholamine and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT₄) receptors. Endocr Relat Cancer 2009;16:281-90
8. Lefebvre H, Duparc C, Cartier D, Contesse V, Perraudin V, Bertherat J, Plouin PF, Reznik Y, Kuhn JM, Louiset E. Autocrine/paracrine regulations of steroidogenesis in adrenocortical hyperplasias and tumors. Ann Endocrinol (Paris) 2009;70:192-3
9. Letavernier E, Peyrard S, Amar L, Zinzindohoué F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2009;27: [letter]
10. Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M. Saliva as a medium for aldosterone measurement in repeated sampling studies. Steroids 2009;74:853-8
11. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009;53:605-10
12. Matrozova J, Steichen O, Amar L, Zacharieva S, Jeunemaitre X, Plouin PF. Metabolic effects of aldosterone. Hypertension 2009;53:e38 [letter]
13. Pellerin O, Garçon P, Beyssen B, Raynaud A, Rossignol P, Jacquot C, Plouin PF, Sapoval M. Spontaneous renal artery dissection: long-term outcomes after endovascular stent placement. J Vasc Interv Radiol 2009;20:1024-30
14. Plouin PF, Amar L. Does stenting for atherosclerotic renovascular disease improve blood pressure and kidney function better than medical treatment? Pol Arch Med Wewn 2009;119:612‑3
15. Porchay-Baldérelli I, Péan F, Emery N, Maimaitiming S, Bellili N, Travert F,Mohammedi K, Roussel R, Marre M, Fumeron F et al; DIABHYCAR Study Group. Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and high-density lipoprotein cholesterol and coronary heart disease in a population with type 2 diabetes mellitus. Metabolism 2009;58:74-9
16. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruïne AP, Maher ER, Tissier F, Méatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, François J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764-71

Maj Février 2019

Le centre d’hypertension a créé ce site pour mieux vous informer. Visitez le.

Depuis cette page, voici quelques réponses aux questions souvent posées.

1/ Contacter et connaitre le centre

• Comment contacter les secrétariats ?
• Comment venir sur place ?
• Comme se déroule une consultation ?
• Comme se déroule une hospitalisation ?
• Que faire en cas d’urgence ?
• Aide à la gestion du stress
• Aide pour l’arrêt du tabac
• Préparer sa consultation
• Téléconsultations
• Télécharger la fiche de notation d’automesure

2/ Recherche

• Pourquoi participer aux activités de recherche ?
• Qu’est ce que la dénervation rénale ?
• La dysplasie fibromusculaire peut-elle toucher plusieurs artères ?

3/ Demander un rendez-vous par courriel

Pour prendre un rendez-vous par courriel, cliquez ici

 

 

4/ Automesure de la tension artérielle

Pour enregistrer vos mesures, faire un compte rendu, comprendre vos résultats, utilisez le site automesure.com

<nsbp;></nsbp;>

5/ Hypertension artérielle et  maladies vasculaires

• Adénome de Conn
• Artérite des membres inférieurs
• Biscuspidie aortique familiale
• Dysplasie fibromusculaire (Fibrodysplasie)
• Glandes surrénales et hypertension artérielle : vidéo pour voir comment nous vous recevons dans notre service
• Hypertension artérielle et maladie rénale
• Hyperaldostéronisme primaire
• Maladie de Buerger
• Maladie de Takayasu
• Phéochromocytome
• Sténose de l’artère rénaleSyndrome d’Ehlers-Danlos vasculaire
• VHL (maladie de Von Hippel Landau)

6/ Conseils pour mieux vous soigner

•  Médicaments contenant du valsartan ou irbésartan : réponses à vos questions

•  Que penser des génériques pour soigner mon hypertension ?

• Docteur, je prends de la levure de riz rouge pour mon cholestérol. Qu’en pensez-vous ?

• Si vous avez fait un accident vasculaire cérébral : info à connaître

• Conseils diététiques

• Certains traitements contre le cancer élèvent la tension : lesquels et comment puis-je me surveiller ?

Rédaction décembre 2018-MAJ juillet 2020

Ce site Internet est celui de l’unité d’hypertension artérielle de l’Hôpital Européen Georges Pompidou (Paris – France) labellisé Centre d’excellence en hypertension artérielle par la Société Européenne d’Hypertension artérielle et la Société française d’hypertension artérielle.

Historique

La vitalité de l’école Française d’hypertension artérielle est l’héritage de Paul Milliez (1912-1994) qui a été le premier à organiser la prise en charge des cas difficiles d’hypertension artérielle dans un service réunissant toutes les facilités et moyens nécessaires. Dans sa suite, P Corvol et J Ménard, M Azizi, G Bobrie, G Chatellier, X Jeunemaitre, S Laurent et PF Plouin ont maintenu, avec tous les membres de leurs équipes, cette unité de lieu et d’action à l’HEGP et l’ont étendue à la génétique et à l’épidémiologie clinique.

Nécessité d’un centre spécialisé

L’hypertension artérielle requiert un recours spécialisé quand elle est sévère, réfractaire, compliquée ou relevant de causes précises ou rares. Quatre-vingts pourcent des patients adressés dans le centre par les médecins correspondants (libéraux ou hospitaliers) relèvent de ces situations. Le centre dispose pour ces cas de tests biologiques (hormones périphériques ou dans les veines surrénales, génotypage, dosages de médicaments) pour lesquels avons défini nos valeurs de référence et seuils d’intervention, de toutes les formes d’imagerie (en coupes, intravasculaire et scintigraphique) et d’un monitorage par télémédecine. En cas d’HTA secondaire, notre rôle est d’établir le diagnostic et l’indication thérapeutique ; de contacter les radiologues ou les chirurgiens spécialisés ; et d’encadrer les traitements invasifs. Nos publications fournissent à ces patients une information précise sur les risques et les bénéfices des procédures engagées. Nous formons les futurs spécialistes en HTA. Notre recherche contribue à une meilleure connaissance physiopathologique de l’HTA et de ses traitements.

Politique de soins

Le personnel d’accueil distingue les patients nouveaux (qui bénéficient d’une pré-consultation) et les patients anciens pour limiter le délai de consultation des nouveaux patients. Soucieuse de l’équité d’accueil des patients, aucun des médecins relevant du centre d’hypertension artérielle n’offre de possibilité d’accueil privée pour influencer ce délai. La plupart des patients sont suivis par leur médecin personnel après intervention ou mise au point d’un programme thérapeutique. Dans un petit nombre de cas, une surveillance prolongée est proposée. Notre centre n’a pas vocation à suivre régulièrement les patients ne présentant pas de difficulté de prise en charge médicale ou de particularité clinique (maladies rares par exemple).

Réseaux et centres de référence

Le centre anime plusieurs réseaux scientifique : COMETE (COrtico et MEdullo-surrénale, les Tumeurs Endocrines) ; PGL-NET (ParaGangLioma NETwork) ; ARCADIA/PROFILE (Assessment of Renal and Cervical Artery DysplasIA Register et PROgression of FIbromuscular Lesions) et EN2iLA (European Network for Non Invasive Investigation of Large Arteries) ; enfin le réseau des centres d’excellence français. Les membres du CE de l’HEGP appartiennent au centre national de référence des maladies vasculaires rares (dysplasie fibromusculaire, Takayasu, Buerger, Elhers-Danlos vasculaire) et aux Unités Pilote de Coordination des tumeurs malignes de la surrénale et de la maladie de von Hippel-Lindau. Pour en savoir plus voir la rubrique Recherche sur ce site .

Programmes de recherche

Le centre coordonne de nombreux programmes (ANR, INCa, INSERM, FRM, PHRC) qui ont donné lieu à des centaines de publications scientifiques. Le centre de l’HEGP est le seul centre en France impliqué dans le développement international précoce (Phase I-II) des nouveaux traitements médicamenteux de l’ HTA. Le recrutement, la culture scientifique et les moyens humains et techniques confèrent au centre la masse critique nécessaire à un site de référence en recherche clinique et translationnelle.

Publications et activité pédagogique

Le centre a publié plus des centaines d’articles originaux, accueille des médecins étrangers pour des stages d’au moins 4 mois et assure la formations des étudiants.

La formation

Le centre forme à tous les aspects de l’HTA les étudiants, les internes en DES de différentes spécialités (cardiologie, endocrinologie, médecine générale, médecine interne, néphrologie), des médecins étrangers. et des infirmières

La visibilité internationale

L’individualisation du centre en HTA de l’HEGP – et à plus forte raison du réseau des CE en HTA qu’il anime – augmente la visibilité internationale de ses membres sur le plan académique et vis-à-vis de partenaires industriels.

 

Centre hypertension HEGP : classé N°1 en France par Le Point en 2018

Avec une note de 18,9/20, le centre d’hypertension artérielle de l’Hôpital Européen Georges Pompidou (HEGP-Paris) est premier au classement de la Revue Le Point (25/08/2018). Ce classement tient compte de plusieurs critères : le fait d’être un centre d’excellence labellisé par la Société Européenne d’hypertension artérielle, l’activité, la disponibilité d’un centre de réanimation cardiaque proche, la notoriété, la durée de séjour, la proportion de patients vus en ambulatoire. L’activité du centre HEGP est de loin la plus importante avec la plus forte notoriété. L’unité d’hypertension artérielle occupe la première place du classement du Point de façon consécutive depuis 2013.

Rédaction centre-hypertension.org.  Mise à jour décembre 2018.

Sur cette page, la liste des protocoles de recherche clinique menés par notre centre

1°) Nouveaux

– Etude ESTIM-RHTN Nouveau traitement dans l’hypertension artérielle sévère résistante

2°) En cours ou achevés

– Essai QGC001: Nouveau médicament dans l’hypertension artérielle légère
– Etude MEDYA(Fibrodysplasie musculaire)
РEtude COEUR ALDO (Pathologie des surr̩nales)
РEtude COMETE (Pathologie des surr̩nales)
РEtude Firstmappp (Pathologie des surr̩nales)
– Etude SPARTE  : Stratégie de prévention cardiovasculaire basée sur la rigidité artérielle
РD̩nervation r̩nale
– Etude PHARES (Amélioration du traitement de l’hypertension artérielle)
– Etude Hy-Quest (Autoquestionnaire du sujet hypertendu)
–Etude Arcadia (la fibrodysplasie peut toucher plusieurs territoires artériels

MAJ  septembre 2017

Le centre coordonne de nombreux programmes (ANR, INCa, INSERM, FRM, PHRC) qui ont donné lieu à des centaines de publications: récemment ARCADIA et PROFILE pour la dysplasie fibromusculaire; COMETE, son une extension européenne ENS@T, ISPA (Integrated Study of Primary Aldosteronism) et PGL-EVA pour les tumeurs surrénales et apparentées; HTN-2 (dénervation rénale) et PHARES (Prise en charge de l’Hypertension Artérielle RESistante au traitement) pour l’HTA réfractaire ; AMETHYST (Aneurysm, METalloproteinases and HYpertension STudy) pour la physiopathologie artérielle. Le CE participe à de nombreux programmes internationaux dont CORAL (Cardiovascular Outcomes in renal Atherosclerotic Lesions), STAR (STent placement for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery) et TNH (Transatlantic Network in Hypertension, Réseau Leducq). Le centre de l’HEGP est le seul centre en France impliqué dans le développement international précoce (Phase I-II) des nouveaux traitement médicamenteux de l’ HTA.